Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • A-101: Phase III started

    Aclaris Therapeutics Inc. (NASDAQ:ACRS), Malvern, Pa. Product: A-101 Business: Dermatology Molecular target: NA Description: High-concentration hydrogen peroxide topical solution Indication: Treat seborrheic keratosis …

    Published on 2/8/2016
  • ALKS 7119: Phase I started

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: ALKS 7119 Business: Neurology Molecular target: NMDA receptor Description: NMDA receptor antagonist and serotonin (5-HT) reuptake inhibitor Indication: Treat …

    Published on 2/8/2016
  • Allogeneic mesenchymal bone marrow cells: Completed Phase I/IIa enrollment

    Stemedica Cell Technologies Inc., San Diego, Calif. Product: Allogeneic mesenchymal bone marrow cells Business: Neurology Molecular target: NA Description: Allogeneic adult mesenchymal bone marrow cells Indication: …

    Published on 2/8/2016
  • Anti-VEGF/Ang2 Nanobody: Phase I started

    Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Boehringer Ingelheim GmbH, Ingelheim, Germany Product: Anti-VEGF/Ang2 Nanobody (BI 836880) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF); …

    Published on 2/8/2016
  • BIND-014: Completed Phase II enrollment

    Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Product: BIND-014 Business: Cancer Molecular target: Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Description: Polymeric nanoparticle containing …

    Published on 2/8/2016
  • BIND-014: Phase II ongoing

    Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Product: BIND-014 Business: Cancer Molecular target: Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Description: Polymeric nanoparticle containing …

    Published on 2/8/2016
  • BioChaperone Lispro: Phase Ib started

    Adocia S.A. (Euronext:ADOC), Lyon, France Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: BioChaperone Lispro Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Ultra-fast …

    Published on 2/8/2016
  • Coversin: Phase Ib started

    Akari Therapeutics plc (NASDAQ:AKTX), New York, N.Y. Product: Coversin Business: Neurology Molecular target: Complement 5 (C5) Description: Complement 5 (C5) inhibitor, which prevents the release of C5a and formation of…

    Published on 2/8/2016
  • Darleukin: Phase III started

    Philogen S.p.A., Siena, Italy Product: Darleukin (L19-IL2) Business: Cancer Molecular target: Interleukin-2 (IL-2) Description: Fusion protein consisting of the human vascular targeting antibody L19 and IL-2 Indication:…

    Published on 2/8/2016
  • Ecopipam: Phase IIb ongoing

    Psyadon Pharmaceuticals Inc., Germantown, Md. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Ecopipam (PSYRX 101) (formerly SCH 39166) Business: Neurology Molecular target: Dopamine D1 receptor Description: …

    Published on 2/8/2016
  • Eflapegrastim: Phase III started

    Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940), Seoul, South Korea Product: Eflapegrastim (LAPS-GCSF) (HM10460A, SPI-2012) Business: Hematology Molecular …

    Published on 2/8/2016
  • Entolimod: Phase II started

    Cleveland BioLabs Inc. (NASDAQ:CBLI), Buffalo, N.Y. Product: Entolimod (Protectan) (CBLB502) Business: Cancer Molecular target: Toll-like receptor 5 (TLR5) Description: Radioprotectant derivative of the toll-like …

    Published on 2/8/2016
  • FFP104: Phase II started

    Fast Forward Pharmaceuticals B.V., Utrecht, the Netherlands PanGenetics B.V., Utrecht, the Netherlands Product: FFP104 (formerly PG102) Business: Hepatic Molecular target: CD40 Description: Deimmunized mAb against CD40 …

    Published on 2/8/2016
  • FFP104: Phase II started

    Fast Forward Pharmaceuticals B.V., Utrecht, the Netherlands PanGenetics B.V., Utrecht, the Netherlands Product: FFP104 (formerly PG102) Business: Autoimmune Molecular target: CD40 Description: Deimmunized mAb against …

    Published on 2/8/2016
  • Fibromun: Phase III started

    Philogen S.p.A., Siena, Italy Product: Fibromun (L19-TNF) Business: Cancer Molecular target: Tumor necrosis factor (TNF) Description: Anti-EDB human antibody L19 that is fused to human tumor necrosis factor (TNF) …

    Published on 2/8/2016
  • Fostamatinib disodium: Completed Phase III enrollment

    Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Product: Fostamatinib disodium (formerly R788, tamatinib fosdium) Business: Autoimmune Molecular target: Spleen tyrosine kinase (SYK) Description: …

    Published on 2/8/2016
  • GEN-003: Phase IIb started

    Genocea Biosciences Inc. (NASDAQ:GNCA), Cambridge, Mass. Product: GEN-003 Business: Infectious Molecular target: Infected cell polypeptide 4 (ICP4) Description: T cell vaccine consisting of the infected cell polypeptide…

    Published on 2/8/2016
  • HMPL-523: Phase I started

    Hutchison China MediTech Ltd. (LSE:HCM), Hong Kong, China Product: HMPL-523 Business: Cancer Molecular target: Spleen tyrosine kinase (SYK) Description: Small molecule inhibitor of spleen tyrosine kinase (SYK) …

    Published on 2/8/2016
  • IVA337: Phase IIb started

    Inventiva S.A.S., Dijon, France Product: IVA337 Business: Autoimmune Molecular target: NA Description: Small molecule targeting an undisclosed nuclear receptor Indication: Treat systemic sclerosis Endpoint: Change from …

    Published on 2/8/2016
  • Meloxicam: Phase III started

    Recro Pharma Inc. (NASDAQ:REPH), Malvern, Pa. Product: Meloxicam (N1539) Business: Neurology Molecular target: Cyclooxygenase-2 (COX-2) Description: Cyclooxygenase-2 (COX-2) inhibitor developed using NanoCrystal …

    Published on 2/8/2016
  • Meloxicam: Phase III started

    Recro Pharma Inc. (NASDAQ:REPH), Malvern, Pa. Product: Meloxicam (N1539) Business: Neurology Molecular target: Cyclooxygenase-2 (COX-2) Description: Cyclooxygenase-2 (COX-2) inhibitor developed using NanoCrystal …

    Published on 2/8/2016
  • Methoxyamine: Phase II started

    Tracon Pharmaceuticals Inc. (NASDAQ:TCON), San Diego, Calif. Product: Methoxyamine (TRC102) Business: Cancer Molecular target: Not applicable Description: Small molecule inhibitor of the DNA base-excision repair pathway…

    Published on 2/8/2016
  • MIV-711: Phase IIa started

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Product: MIV-711 Business: Autoimmune Molecular target: Cathepsin K (CTSK) Description: Reversible small molecule inhibitor of cathepsin K (CTSK) Indication: Treat …

    Published on 2/8/2016
  • Patisiran: Completed Phase III enrollment

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), Cambridge, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Patisiran (GZ438027, GENZ438027, ALN-TTR02) Business: Endocrine/Metabolic Molecular target: …

    Published on 2/8/2016
  • PF-4937319: Development discontinued

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: PF-4937319, PF-04937319 Business: Endocrine/Metabolic Molecular target: Glucokinase (GCK) (GK) Description: Partial glucokinase (GCK; GK) activator Indication: Treat Type …

    Published on 2/8/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993